Evidence map›Paper›PMID 36267739›Full record

ArticleAnnals of translational medicine2022

CBX4 contributes to radioresistance by regulating autophagic activity in esophageal squamous cell carcinoma.

Hongcheng Zhu, Hui Chen, Guangzong Chen, Ming Liu, Li Chu, Yu Gu, Yun Chen, Chi Zhang, Qin Qin, Yanan Chen and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Hongcheng Zhu *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui Chen *Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guangzong Chen *Department of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Ming LiuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Li ChuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yu GuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yun ChenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Chi ZhangDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qin QinDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yanan ChenDepartment of Radiation Oncology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, China.
Weiwei ChenDepartment of Radiotherapy, Yancheng Third People's Hospital, The Affiliated Yancheng Hospital of Southeast University Medical College and The Sixth Affiliated Hospital of Nantong University, Yancheng, China.
Jianhong FanDepartment of Gynecology, Renhe Hospital, Shanghai, China.
Yongzhan NieState Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, China.
Junqiang ChenDepartment of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Shixiu WuDepartment of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China.
Xinchen SunDepartment of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Weixin ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNJiangsu Province Hospital · CNShanghai Medical College of Fudan University · CNAir Force Medical University · CNChangzhou No.2 People's Hospital · CNFujian Medical University · CNNanjing Medical University · CNRenji Hospital · CNShanghai Institute of Hematology · CNSoochow University · CNYancheng Third People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The function of Chromobox 4 (CBX4) function has attracted attention in many cancer types due to its unique biological role; however, its mechanism in esophageal squamous cell carcinoma (ESCC) under radiotherapeutic treatment has not yet been investigated. Methods: Silencing of CBX4 was carried out in TE-13 and KYSE-150 cell lines. Cell proliferation, radiosensitivity, DNA damage, apoptosis, and cell cycle distribution were determined by Cell Counting Kit-8 (CCK-8), colony formation assay, immunofluorescence, flow cytometry, and immunoblot Results: Knockdown of CBX4 resulted in reduced tumor growth and enhanced radio-response Conclusions: By regulating autophagic activity, CBX4 contributes to radioresistance. Targeting CBX4 might constitute an efficient approach for increasing radiosensitivity in ESCC.

Indexed as

autophagyChromobox 4 (CBX4)Esophageal squamous cell carcinoma (ESCC)radioresistanceradiotherapy

Identifiers

PMID36267739
PMCPMC9577798
OpenAlexW4211248755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.